MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Illumina Inc

Closed

SectorHealthcare

77.58 2

Overview

Share price change

24h

Current

Min

75

Max

78.05

Key metrics

By Trading Economics

Income

187M

Sales

24M

1.1B

EPS

0.86

Profit margin

16.938

Employees

8,970

EBITDA

54M

283M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+48.81% upside

Dividends

By Dow Jones

Next Earnings

8 maj 2025

Market Stats

By TradingEconomics

Market Cap

-10B

11B

Previous open

75.58

Previous close

77.58

Technical Score

By Trading Central

Confidence

Bullish Evidence

Illumina Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 mar 2025, 09:18 UTC

Hot Stocks

Stocks to Watch Tuesday: Tesla, Oracle, Delta, Nvidia -- WSJ

10 mar 2025, 21:07 UTC

Top News

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban -- WSJ

10 mar 2025, 20:01 UTC

Top News

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban -- WSJ

4 mar 2025, 10:56 UTC

Hot Stocks

Stocks to Watch Tuesday: Illumina, Nvidia, Stellantis -- WSJ

Peer Comparison

Price change

Illumina Inc Forecast

Price Target

By TipRanks

48.81% upside

12 Months Forecast

Average 113.47 USD  48.81%

High 160 USD

Low 75 USD

Based on 19 Wall Street analysts offering 12 month price targets forIllumina Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

9

Buy

8

Hold

2

Sell

Technical Score

By Trading Central

75.05 / 76.3Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.